Save time and jump to the most important pieces.
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
Head and neck cancer patients treated with Multikine who had complete or partial tumor responses before surgery had improvements in overall survival, suggesting pre-surgical tumor response is a strong indicator of efficacy and leads to improved overall survival A third-party head and neck cancer study published in "Cancer Cell" confirms the observation that pre-surgical tumor responses in head and neck cancer leads to improved survival CEL-SCI Corporation (NYSE:CVM) today announced that a study titled "Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies" by Li Housaiyin et. al., Cancer Cell (2025) provides support for CEL-SCI's approach aimed at see
Data published in peer-reviewed scientific journal Pathology and Oncology Research Quality of life improvements included reduction in or cessation of pain in the head and neck area, improvement or complete restoration in ability to eat, drink, and swallow, ability for selfcare including walking and using the toilet, and improved emotional wellbeing Complete responders to Multikine treatment reported a 100% (wherein all respondents scored the highest possible improvement from baseline) on 60% (39/65) quality of life measures 89.4% of partial responders to Multikine reported improved quality of life measures Multikine is headed into a final confirmatory Registration Study in head and neck
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced best-efforts offering of 16,000,000 shares of its common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof). Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, is approximately $2,560,000. All the shares and Pre-Funded Warrants in the offering were offered by the Company The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate purposes, and working capital. ThinkEquity acted as sole p
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
SC 13G/A - CEL SCI CORP (0000725363) (Subject)
SC 13G/A - CEL SCI CORP (0000725363) (Subject)
SC 13G/A - CEL SCI CORP (0000725363) (Subject)
DEF 14A - CEL SCI CORP (0000725363) (Filer)
PRE 14A - CEL SCI CORP (0000725363) (Filer)
8-K - CEL SCI CORP (0000725363) (Filer)
CEL-SCI Corporation (NYSE:CVM) today reported financial results for the quarter ended June 30, 2024, as well as key recent clinical and corporate developments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815767286/en/The table includes detailed results from the bias analysis. (Graphic: Business Wire) Clinical and Corporate Developments include: In July 2024, following the end of the third fiscal quarter, CEL-SCI reported the results of a bias analysis. The bias analysis, a standard process to ensure a trial's findings are reliable, was conducted in preparation for CEL-SCI's upcoming confirmatory Registration Study. This
CEL-SCI Corporation (NYSE:CVM) today announced that Robert ("Bob") Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital formation strategies and partnerships to drive an efficient capital structure. During his career as CEO or President of private and publicly traded companies in the healthcare sector, Bob negotiated over a half dozen exits and more than $750 million in capital transactions including IPOs, secondary offerings, and debt in
CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as investment banking and strategic advisory services. He has served as an officer or director for a number of companies including several biotech companies: Xcovery, Ocimum/Genelogic and Helix BioPharma. Prior to that, Mr. Gobbo worked in the financial industry for Lazard LLC, Swiss Bank Corporation, the European Bank for Reconstruction and Development, Natixis Bleichroeder, Inc., and International Finance Corporation